Isabel Ferreira, PharmD, PhD

Global Scientific Director
Takeda Pharmaceuticals International AG, Switzerland

Poster(s):

• P-114: In-class transition (iCT) from parenteral bortezomib (V) to oral ixazomib in multiple myeloma (MM) by age and frailty status: Updated subgroup analysis from the fully accrued US MM-6 study
  Wednesday, September 27, 2023

  1:30 PM – 2:30 PM EEST